Osteogenesis of osteogenic matrix cell sheets preserved in culture medium in a rat model

Tsutomu Kira1,2, Manabu Akahane3, Noriko Ouji-Sageshima4, Takamasa Shimizu1, Tadanobu Onishi1, Shohei Omokawa1,5, Toshihiro Ito4, and Yasuhito Tanaka1,2

Abstract
Osteogenic matrix cell sheets (OMCSs) are ideal for bone regeneration. Transportation of OMCSs may be necessary, during which their osteogenic ability must be maintained. Here, we evaluated different media and temperatures for OMCS preservation. Bone marrow stromal/stem cells (BMSCs) were obtained from Fischer rats and analyzed for stem cell markers by flow cytometry. OMCSs were prepared from BMSCs by treatment with dexamethasone and ascorbic acid phosphate. After OMCS collection, they were stored in minimum essential medium (MEM) or Hank’s balanced salt solution (HBSS) at 37, 22, or 4 °C for 24 hours. Cell viability and cytotoxic effects in the preservation conditions were determined by adenosine triphosphate (ATP) contents and lactate dehydrogenase (LDH) release, respectively. Osteogenesis was assessed by subcutaneously implanting preserved OMCSs around β-tricalcium phosphate ceramic disks into syngeneic rats. Implants were evaluated by alkaline phosphatase (ALP) activities, osteocalcin contents, and histology. Mesenchymal stem cells comprised 51% of primary cultured BMSCs. ATP contents were significantly different in OMCSs stored in MEM or HBSS at 22 °C and 4 °C. LDH release was significantly different in OMCSs stored in HBSS at 22 °C and 4 °C. The highest LDH release was observed in OMCSs stored in HBSS at 37 °C. ALP activities and osteocalcin contents were the lowest in implanted OMCSs stored in HBSS at 37 °C at four weeks after subcutaneous implantation. There was a significant difference in the osteocalcin levels of implanted OMCSs stored in MEM at 37 °C and HBSS at 4 °C. Abundant bone tissue around and inside disks was found in histological sections of OMCSs stored in all preservation conditions except for MEM and HBSS at 37 °C. Maintaining the osteogenic ability of OMCSs during transport is important, and preservation of OMCSs in MEM or HBSS at 4 °C is a simple and inexpensive method.

Keywords
cell sheet, osteogenesis, bone marrow stromal/stem cell, mesenchymal stem cell, cell preservation

Introduction
Cell-based therapy, carried out in a cell processing center (CPC), has been applied clinically1–3. In particular, mesenchymal stem cells (MSCs) have attracted great interest for bone, tendon, muscle, and nerve regeneration because MSCs are multipotent and can differentiate into osteoblasts4,5, chondrocytes6; and neurons6,7. There is a huge demand for cell therapy using MSCs at general hospitals without a CPC. CPCs are generally established in university hospitals; the high expense of a CPC means that general hospitals cannot operate them. Recently, cell sheet technology has emerged as a cell transplantation system without a scaffold and has been used for regenerative treatments of the heart8, cornea9, and liver10. We have reported the utilities of osteogenic matrix cell sheets (OMCSs) derived from bone

1 Department of Orthopedic Surgery, Nara Medical University, Kashihara, Nara, Japan
2 The Center for Rheumatic Diseases, Nara Medical University Hospital, Kashihara, Nara, Japan
3 Department of Public Health, Health Management and Policy, Nara Medical University Faculty of Medicine, Kashihara, Nara, Japan
4 Department of Immunology, Nara Medical University, Kashihara, Nara, Japan
5 Department of Hand Surgery, Nara Medical University, Kashihara, Nara, Japan

Submitted: May 7, 2018. Accepted: June 2, 2018.

Corresponding Author:
Tsutomu Kira, Department of Orthopedic Surgery, Nara Medical University, 840 Shijo-cho, Kashihara, Nara 634-8522, Japan.
Email: g212005@naramed-u.ac.jp

Creative Commons Non Commercial CC BY-NC: This article is distributed under the terms of the Creative Commons Attribution-NonCommercial 4.0 License (http://creativecommons.org/licenses/by-nc/4.0/) which permits non-commercial use, reproduction and distribution of the work without further permission provided the original work is attributed as specified on the SAGE and Open Access pages (https://us.sagepub.com/en-us/nam/open-access-at-sage).
marrow stromal/stem cells (BMSCs) for bone reconstruction and treatment of pseudarthrosis\textsuperscript{11–15}. However, a CPC is necessary to prepare cultured cells and cell sheets, and cell sheets must be preserved and transported to general hospitals that have no CPC for clinical use. Transportation of OMCSs while conserving their activities enables the application of cell sheets in various diseases and injuries. There is currently no expedient and equable technique to conserve and transport cell sheets. The aim of this study was to develop a method for conserving and transporting cell sheets.

**Materials and Methods**

**Ethics Statement**

The care and handling of animals used in this study was approved by the institutional animal care and use committee of Nara Medical University and met the standards of the National Institutes of Health (protocol#: 11538).

**Preparation of Bone Marrow Cells**

Seven-week-old male Fischer 344 rats were purchased from CLEA Japan, Inc. (Tokyo, Japan) for use as donors and recipients. BMSCs were obtained by flushing out the rat femur shafts with 10 ml culture medium consisting of minimal essential medium (Nacalai Tesque, Kyoto, Japan) containing 15% fetal bovine serum and antibiotics (100 U/ml penicillin and 100 \(\mu\)g/ml streptomycin; Nacalai Tesque). The BMSCs were incubated at 37\(^\circ\)C in a humidified atmosphere with 5% CO\(_2\). At confluency (approximately day 14), the primary cultured BMSCs were harvested using a 0.25% trypsin/EDTA solution (Nacalai Tesque) to obtain a cell suspension.

**Analysis of Cell Surface Markers**

To demonstrate MSCs among BMSCs after primary culture, cell surface CD markers were analyzed by flow cytometry (FACSCalibur, Becton Dickinson, Franklin Lakes, NJ, USA).

Single cell suspensions of BMSCs in phosphate-buffered saline (PBS) were exposed to antibodies directly coupled with a fluorochrome for 30 min on ice. The antibodies used were anti-CD90 (Becton Dickinson) or Mouse IgG1 \(\kappa\) isotype (control; Becton Dickinson) and anti-CD29 (Becton Dickinson) or Hamster IgM \(\kappa\) isotype (control; Becton Dickinson) directly coupled to phycoerythrin and anti-CD90 (Becton Dickinson) or Mouse IgG1 \(\kappa\) isotype (control; Becton Dickinson) coupled to fluorescein-5-isothiocyanate as representative stem cell markers. Similarly, anti-CD45 (eBioscience, San Diego, CA, USA) or Mouse IgG1x isotype (control; eBioscience) directly coupled to allophycocyanin was used as a representative marker of hematopoietic and endothelial stem cells.

**Cell Sheet Preparation and Preservation**

We have previously reported a method to prepare OMCSs\textsuperscript{11}. Briefly, BMSCs obtained from primary culture were seeded at a density of \(1 \times 10^4\) cells/cm\(^2\) onto 60-mm cell culture dishes for subculture in regular medium containing 10 nM dexamethasone (Sigma, St. Louis, MO, USA) and 0.28 mM ascorbic acid phosphate (AseP; L-ascorbic acid phosphate magnesium salt n-hydrate; Wako Pure Chemical Industries, Kyoto, Japan). OMCSs were formed by culture to confluency (approximately 2 weeks), and then rinsed twice with PBS (Gibco Life Technologies, Carlsbad, CA, USA). The sheet was lifted by a mechanical retrieval method using a cell scraper.

OMCSs were divided into seven groups according to the preservation method: fresh (control group), storage in culture medium at 37\(^\circ\)C (37\(^\circ\)C MEM group), storage in culture medium at room temperature (22\(^\circ\)C MEM group), storage in culture medium at 4\(^\circ\)C (4\(^\circ\)C MEM group), storage in Hank’s balanced salt solution (HBSS; Gibco) at 37\(^\circ\)C (37\(^\circ\)C HBSS group), storage in HBSS at 22\(^\circ\)C (22\(^\circ\)C HBSS group), and storage in HBSS at 4\(^\circ\)C (4\(^\circ\)C HBSS group). For preservation, OMCSs were picked up using tweezers and placed into a 50-ml tube (Falcon) with 50 ml culture medium or HBSS (six OMCSs per tube). Tubes were then transferred to an incubator (37\(^\circ\)C), a clean bench (room temperature: 22\(^\circ\)C), or refrigeration chamber (4\(^\circ\)C) and stored for 24 h.

**Cell Viability and Cytotoxicity Assays**

To investigate the viability of OMCSs before and after preservation, we employed a method based on adenosine triphosphate (ATP) content (TOYO B-NET, Tokyo, Japan). Furthermore, lactate dehydrogenase (LDH) activity in preservation media was measured to assess the cytotoxicity of OMCS preservation using a LDH Cytotoxicity Detection Kit (Takara Bio Inc., Shiga, Japan).

Total cellular ATP content was measured in an OMCS plated in a 60-mm dish. The OMCS was lysed with 1 ml lysis buffer and placed directly into the chamber of a luminometer (SpectraMax, Molecular Devices, San Jose, CA, USA). Light emission was recorded after addition of 1 ml luciferin-luciferase solution. ATP Standard Solution (TOYO B-NET) was used for the standard.

To evaluate LDH activity, preservation supernatants were collected and transferred to new tubes. The LDH activity was measured by determining absorbance at 490 nm with an automated microplate reader (SpectraMax M2, Molecular Devices). LDH Standard Solution (Roche, Tokyo, Japan) was used for the standard.

**Implantation of Tricalcium Phosphate Constructs Wrapped with an OMCS**

Sterilized porous \(\beta\)-tricalcium phosphate (TCP) ceramics (Superpore; disks: 5 mm in diameter; 2 mm thick; 65%
porosity) were purchased from PENTAX (Tokyo, Japan). TCP constructs were prepared by wrapping OMCSs from each group around the TCP immediately prior to transplantation. TCP disk constructs were implanted subcutaneously into the backs of syngeneic rats.

**Biochemical Analysis**

The alkaline phosphatase (ALP) activities and osteocalcin contents of harvested constructs were measured as reported previously. After homogenization of each TCP construct using a microhomogenizer in 1 ml of 0.2% Nonidet P-40 (NP-40), homogenized TCP was centrifuged at 12,000 rev/min for 10 min at 4°C. A 10 µl aliquot of the supernatant was combined with 56 mmol/l amino-2-methylpropanediol buffer containing 10 mmol/l p-nitrophenyl phosphate and 1 mmol/l MgCl₂. The combined supernatant was incubated for 30 min at 37°C, and the reaction was stopped by addition of 0.2 N NaOH. The ALP activity was calculated by determining the absorbance of p-nitrophenol released at 410 nm using a spectrophotometer.

After extraction with 0.2% NP-40 in 4 ml of 20% formic acid for 2 weeks at 4°C, osteocalcin was extracted from the sediment. A 0.5 ml aliquot of the extract was applied to a prepacked Sephadex G-25 column (NAP-5 column; Amersham Pharmacia Biotech AB, Uppsala, Sweden) and eluted with 10% formic acid. The protein fractions were pooled and dried. After dissolution in 0.5 ml ELISA sample buffer, the osteocalcin content was assayed using a Rat Osteocalcin ELISA Kit (DS Pharma Biomedical, Osaka, Japan).

**Histological Examination**

Four weeks after subcutaneous implantation, the implanted TCP disks with OMCSs were harvested and bone formation was evaluated histologically. The disks were fixed in buffered formalin (Wako Pure Chemical Industries). Each disk was decalcified with a KCL solution (K-CX solution; Falma, Tokyo, Japan), embedded in paraffin, cut through the middle of the disk parallel to the base, and then stained with hematoxylin and eosin (HE) for histological evaluation.

**Statistical Analysis**

ATP content, LDH activity, ALP activity, and the osteocalcin level are presented as the mean and standard deviation. One-way analysis of variance with post-hoc multiple comparisons using Tukey’s test was conducted to determine statistical significance. Values of \( p < 0.05 \) were considered as statistically significant.

**Results**

**BMSC Surface Markers**

BMSCs were positive for CD29 and CD90, and negative for CD45 as identified by flow cytometry. The CD29⁺ CD90⁺ CD45⁻ population comprised 51% of total cells in each experiment (Fig. 1).

**ATP Contents and LDH Activities after 24 h of Preservation**

There was no statistically significant difference in ATP content between the 22°C MEM and 4°C MEM groups or between the 22°C HBSS and 4°C HBSS groups (Fig. 2(A)). The OMCSs preserved at 22°C or 4°C retained 35–70% ATP content of the control group at 24 h. ATP content in the 37°C MEM and 37°C HBSS groups had
largely decreased to 25% and 1% of those in the control group, respectively.

There were statistically significant differences in LDH release between the 22°C HBSS and 4°C HBSS groups. For LDH activities, there were significant differences between the 22°C HBSS and 4°C HBSS groups. ATP: adenosine triphosphate; LDH: lactate dehydrogenase; MEM: minimum essential medium; HBSS: Hank’s balanced salt solution; ANOVA: analysis of variance

**ALP Activity and Osteocalcin Content of the Implanted TCP Wrapped with Preserved OMCSs**

The ALP activities and osteocalcin content in the 37°C HBSS group were significantly lower compared with those in the other groups. There was a significant difference in osteocalcin levels between 37°C MEM and 4°C HBSS groups. ALP: alkaline phosphatase; MEM: minimum essential medium; HBSS: Hank’s balanced salt solution; ANOVA: analysis of variance

**Histological Evaluation of the Implanted TCP Wrapped with Preserved OMCSs**

Fig. 4 shows representative histological sections (HE staining) of the TCP constructs. Abundant bone tissue around and inside the disks was observed in the sections of all groups except the 37°C MEM and 37°C HBSS groups. Although
Figure 4. Hematoxylin and eosin-stained sections at 4 weeks after implantation into the subcutaneous layer of syngeneic rats. Poor bone formation was found in low magnification images of a β-tricalcium phosphate disk (TCP) in the 37°C MEM group (C and D). Low magnification images of a TCP disk in the 37°C HBSS group (E and F) showed negligible bone formation. Conversely, a high level of bone formation was visible in and around TCP in control (A and B), 22°C MEM (G and H), 22°C HBSS (I and J), 4°C MEM (K and L), and 4°C HBSS (M and N) groups. Asterisks indicate bone tissue. MEM: minimum essential medium; HBSS: Hank's balanced salt solution.
mild new bone was found inside disks in the 37°C MEM group, only trace bone tissue was found.

**Discussion**

Bone regeneration technology has undergone remarkable development and has been applied clinically. We have developed OMCs as a novel cell transplantation technique and reported its effectiveness and utility for bone regeneration using several animal models.

However, in our previous reports, we did not substantiate that BMSCs before subculture included MSCs. The results of flow cytometry in this study indicated that MSCs are an important cell source for OMCs.

Because OMCs abundantly produce bone growth factors and can differentiate to osteocytes, they are relevant materials for osteogenesis. However, cultured cells and cell sheets must be prepared in a CPC to ensure their safety. CPCs are established only in specific institutions such as universities and university hospitals. It is necessary to safely transport cell sheets cultured at a CPC to general hospitals to apply cell sheet-based tissue engineering and regenerative medicine. There have been several reports of transportation of cultured cells. Almost all the transportation techniques involved cryopreservation.

Because cryopreservation reduces the osteogenic abilities of OMCs after thawing, it is not an ideal method for transportation within a short timescale. Although a portable homothermal container has been developed to transport cells attached to culture dishes, it is a large, expensive device. Therefore, the development of an easier and lower-cost method is anticipated.

In our present study, we investigated the osteogenic abilities of OMCs preserved in culture medium or HBSS in plastic tubes for 24 h. After 24 h of preservation, OMCs maintained their sheet form and could be wrapped around a TCP disk. In the viability assays assessing ATP activity and LDH release, OMCs preserved at 22°C or 4°C showed low cell viabilities compared with fresh OMCs. However, the OMCs demonstrated similar osteogenic abilities to fresh OMCs in biochemical analysis of ALP activities and osteocalcin content after subcutaneous implantation of TCP wrapped with the preserved OMCs. A reason for this result is that, even in culture medium or HBSS, cells of OMCs may slowly undergo apoptosis after detachment from culture dishes. However, a considerable number of cells may survive at 22°C. Therefore, the surviving cells could proliferate, differentiate, and secrete growth factors after implantation into the subcutaneous layer with TCP. Therefore, preserved OMCs might maintain their osteogenic ability within 24 h. Because cellular metabolism of OMCs does not decrease at 37°C, it had been speculated that nearly all preserved cells would not survive for 24 h. The current study suggests that OMCs can be transported in plastic tubes containing culture medium or HBSS and applied to bone regenerative treatments. In our study, we evaluated osteogenesis of OMCs on TCP that had been implanted into subcutaneous layers of syngeneic rats. The results indicate that OMCs may promote osteogenesis at a necrotic bone site or bone defect as well as heal at a non-union.

Generally, temperature-responsive culture dishes are widely used to prepare cell sheets. In our study, cell sheets were fabricated from BMSCs by addition of dexamethasone and AscP to the culture medium during subculture, and we harvested the cell sheets by retrieval with scrapers. Because dexamethasone and AscP are inductive differentiating factors, BMSCs can differentiate to osteoblasts in subculture. Moreover, dexamethasone and AscP promote secretion of extracellular matrix. Therefore, the form of the cell sheet could be maintained for 24 h.

Our study has limitations that should be acknowledged. Six OMCs were preserved in a 50 ml tube with 50 ml culture medium or HBSS. The amount of storage solution per sheet might be insufficient for 24 h of preservation. Second, we evaluated osteogenic potentials of OMCs preserved for only 24 h. In a future study, it will be necessary to investigate how long an OMC maintains its osteogenic ability. However, 24 h may be practically adequate for domestic transplantation of OMCs, because the number of CPCs has been increasing. Last, although the current study employed animal experiments using rats, clinical application would be required to evaluate the osteogenic abilities of preserved OMCs derived from human mesenchymal stem cells.

**Conclusions**

The results from this study clearly show that culture medium or HBSS maintain the osteogenic abilities of OMCs within 24 h at 4°C or 22°C. Maintaining the osteogenic ability of OMCs during transport is important, and preservation of OMCs in MEM or HBSS at 4°C or 22°C is a simple, inexpensive, and useful method.

**Acknowledgments**

We thank Ms. Kunda F and Ms. Matsumura M (Nara Medical University) for their technical assistance. We thank Mitchell Arico from Edanz Group (www.edanzediting.com/ac) for editing a draft of this manuscript.

**Author Contribution**

TK conducted the animal experiments and wrote the manuscript; MA designed the study; TK, MA, and NO-S conducted biological analysis; SO, TI, and YT interpreted the results; TO conducted the data analysis.

**Ethical Approval**

This study was approved by the Nara Medical University Medical Ethics Review Committee (protocol#: 11538).

**Statement of Human and Animal Rights**

All procedures in the animal study were approved by the institutional animal care and use committee of Nara Medical University before experiments commenced.
References

1. Ohgushi H, Kotobuki N, Funaoka H, Machida H, Hirose M, Tanaka Y, Takakura Y. Tissue engineered ceramic artificial joint—ex vivo osteogenic differentiation of patient mesenchymal cells on total ankle joints for treatment of osteoarthritis. Biomaterials. 2005;26:4654–61.

2. Wakitani S, Imoto K, Yamamoto T, Saito M, Murata N, Yoneda M. Human autologous culture expanded bone marrow mesenchymal cell transplantation for repair of cartilage defects in osteoarthritic knees. Osteoarthr Cartil. 2002;10:199–206.

3. Kawate K, Yajima H, Ohgushi H, Kotobuki N, Sugimoto K, Ohmura T, Kobata Y, Shigematsu K, Kawamura K, Tamai K, Takakura Y. Tissue-engineered approach for the treatment of steroid-induced osteonecrosis of the femoral head: transplantation of autologous mesenchymal stem cells cultured with beta-tricalcium phosphate ceramics and free vascularized fibula. Artif Organs. 2006;30:960–62.

4. Ohgushi H, Caplan AI. Stem cell technology and bioceramics: from cell to gene engineering. J Biomed Mater Res. 1999;48:913–27.

5. Akahane M, Ohgushi H, Yoshikawa T, Sempuku T, Tamai S, Tabata S, Doi Y. Osteogenic phenotype expression of allogeneic rat marrow cells in porous hydroxyapatite ceramics. J Bone Miner Res. 1999;14:561–8.

6. Zhao HB, Ma H, Ha XQ, Zheng P, Li XY, Zhang M, Dong JZ, Yang YS. Salidroside induces rat mesenchymal stem cells to differentiate into dopaminergic neurons. Cell Biol Int. 2014;38:462–71.

7. Woodbury D, Schwarz EJ, Prockop DJ, Black IB. Adult rat and human bone marrow stromal cells differentiate into neurons. J Neurosci Res. 2000;61:364–70.

8. Kawamura M, Miyagawa S, Fukushima S, Saito A, Miki K, Ito E, Sougawa N, Kawamura T, Daimon T, Shimizu T, Okano T, Toda K, Sawa Y. Enhanced survival of transplanted human induced pluripotent stem cell-derived cardiomyocytes by the combination of cell sheets with the pedicled omental flap technique in a porcine heart. Circulation. 2013;128:S87–S94.

9. Nishida K, Yamato M, Hayashida Y, Watanabe K, Yamamoto Adachi E, Nagai S, Kikuchi A, Maeda N, Watanabe H, Okano T, Tano Y. Corneal reconstruction with tissue-engineered cell sheets composed of autologous oral mucosal epithelium. N Engl J Med. 2004;351:1187–96.

10. Ohki T, Yamato M, Ota M, Takagi R, Murakami D, Kondo M, Sasaki R, Namiki H, Okano T, Yamamoto M. Prevention of esophageal stricture after endoscopic submucosal dissection using tissue-engineered cell sheets. Gastroenterology. 2012;143:582–8. e2.

11. Akahane M, Nakamura A, Ohgushi H, Shigematsu H, Doi Y, Takakura Y. Osteogenic matrix cell-sheet transplantation using osteoblastic cell sheet resulted in bone formation without scaffold at an ectopic site. J Tissue Eng Regen Med. 2008;2:196–201.

12. Inagaki Y, Uematsu K, Akahane M, Morita Y, Ogawa M, Ueha T, Shimizu T, Kura T, Kawate K, Tanaka Y. Osteogenic matrix cell sheet transplantation enhances early tendon graft to bone tunnel healing in rabbits. Biomed Res Int. 2013;2013:842192.

13. Uchihara Y, Akahane M, Shimizu T, Ueha T, Morita Y, Nakasaki S, Kura T, Tohma Y, Kido A, Kawate K, Tanaka Y. Osteogenic matrix cell sheets facilitate osteogenesis in irradiated rat bone. Biomed Res Int. 2015;2015:629168.

14. Ueha T, Akahane M, Shimizu T, Uchihara Y, Morita Y, Nitta N, Kido A, Inagaki Y, Kawate K, Tanaka Y. Utility of tricalcium phosphate and osteogenic matrix cell sheet constructs for bone defect reconstruction. World J Stem Cells. 2015;7:873–82.

15. Kira T, Akahane M, Omokawa S, Shimizu T, Kawate K, Ohnishi T, Tanaka Y. Bone regeneration with osteogenic matrix cell sheet and tricalcium phosphate: an experimental study in sheep. World J Orthop. 2017;8:754–60.

16. Ohgushi H, Doi H, Katuda T, Tamai S, Tabata S, Suwa Y. In vitro bone formation by rat marrow cell culture. J Biomed Mater Res. 1996;32:333–40.

17. Nakamura A, Akahane M, Shigematsu H, Tadokoro M, Morita Y, Ohgushi H, Doi H, Imamura T, Tanaka Y. Cell sheet transplantation of cultured mesenchymal stem cells enhances bone formation in a rat nonunion model. Bone. 2010;46:418–24.

18. Shimizu T, Akahane M, Morita Y, Omokawa S, Nakano K, Kura T, Onishi T, Inagaki Y, Okuda A, Kawate K, Tanaka Y. The regeneration and augmentation of bone with injectable osteogenic cell sheet in a rat critical fracture healing model. Injury. 2015;46:1457–64.

19. Kotobuki N, Hirose M, Machida H, Katou Y, Muraki K, Takakura Y, Ohgushi H. Viability and osteogenic potential of cryopreserved human bone marrow-derived mesenchymal cells. Tissue Eng. 2005;11:663–73.

20. Yoshikawa T, Nakajima H, Takakura Y, Nonomura A. Osteogenesis with cryopreserved marrow mesenchymal cells. Tissue Eng. 2005;11:152–60.

21. Liu G, Shu C, Cui L, Liu W, Cao Y. Tissue-engineered bone formation with cryopreserved human bone marrow mesenchymal stem cells. Cryobiology. 2008;56:209–15.

22. Yin H, Cui L, Liu G, Cen L, Cao Y. Vitreous cryopreservation of tissue engineered bone composed of bone marrow
mesenchymal stem cells and partially demineralized bone matrix. Cryobiology. 2009;59:180–7.

23. Lippens E, Cornelissen M. Slow cooling cryopreservation of cell-microcarrier constructs. Cells Tissues Organs. 2010;192:177–86.

24. Shimizu T, Akahane M, Ueha T, Kido A, Omokawa S, Kobata Y, Murata K, Kawate K, Tanaka Y. Osteogenesis of cryopreserved osteogenic matrix cell sheets. Cryobiology. 2013;66:326–32.

25. Nozaki T, Yamato M, Inuma T, Nishida K, Okano T. Transportation of transplantable cell sheets fabricated with temperature-responsive culture surfaces for regenerative medicine. J Tissue Eng Regen Med. 2008;2:190–5.

26. Okano T, Yamada N, Sakai H, Sakurai Y. A novel recovery system for cultured cells using plasma-treated polystyrene dishes grafted with poly(N-isopropylacrylamide). J Biomed Mater Res. 1993;27:1243–51.

27. Akahane M, Shimizu T, Kira T, Onishi T, Uchihara Y, Imamura T, Tanaka Y. Culturing bone marrow cells with dexamethasone and ascorbic acid improves osteogenic cell sheet structure. Bone Joint Res. 2016;5:569–76.